Budesonide dry-powder inhalation - Sofotec

Drug Profile

Budesonide dry-powder inhalation - Sofotec

Alternative Names: Budecort 200 Novolizer; Budesonide Novolizer; Novolizer Budesonide; Novopulmon 200 Novolizer; S 1320 dry-powder inhalation - Sofotec; Tafen Novolizer

Latest Information Update: 19 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Degussa; Sofotec; University of Groningen
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 05 Aug 2016 Meda has been acquired by Mylan
  • 15 Mar 2016 Biomarkers information updated
  • 07 Nov 2003 Budesonide 200µg Novolizer® is available for licensing outside Germany and major West European countries (http://www.viatris.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top